vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $12.1M, roughly 1.2× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs 1.8%, a 67.0% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs 2.3%). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 0.7%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
CSBR vs TCI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.1M |
| Net Profit | $268.0K | $8.3M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | -28.9% |
| Net Margin | 1.8% | 68.8% |
| Revenue YoY | 11.5% | 2.3% |
| Net Profit YoY | -63.2% | 7577.8% |
| EPS (diluted) | $0.02 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $12.1M | ||
| Q3 25 | $14.0M | $12.8M | ||
| Q2 25 | $12.4M | $12.2M | ||
| Q1 25 | $17.0M | $12.0M | ||
| Q4 24 | $13.5M | $11.8M | ||
| Q3 24 | $14.1M | $11.6M | ||
| Q2 24 | $14.0M | $11.8M | ||
| Q1 24 | $12.0M | $11.9M |
| Q4 25 | $268.0K | $8.3M | ||
| Q3 25 | $-436.0K | $724.0K | ||
| Q2 25 | $-1.8M | $169.0K | ||
| Q1 25 | $4.5M | $4.6M | ||
| Q4 24 | $728.0K | $108.0K | ||
| Q3 24 | $1.3M | $1.7M | ||
| Q2 24 | $-109.0K | $1.5M | ||
| Q1 24 | $-2.5M | $2.5M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | -28.9% | ||
| Q3 25 | -3.8% | -10.9% | ||
| Q2 25 | -16.2% | -6.8% | ||
| Q1 25 | 26.4% | -5.3% | ||
| Q4 24 | 5.4% | -14.3% | ||
| Q3 24 | 9.5% | -14.4% | ||
| Q2 24 | -1.9% | -9.2% | ||
| Q1 24 | -21.4% | -11.2% |
| Q4 25 | 1.8% | 68.8% | ||
| Q3 25 | -3.1% | 5.6% | ||
| Q2 25 | -14.9% | 1.4% | ||
| Q1 25 | 26.4% | 38.5% | ||
| Q4 24 | 5.4% | 0.9% | ||
| Q3 24 | 9.3% | 14.7% | ||
| Q2 24 | -0.8% | 12.7% | ||
| Q1 24 | -21.1% | 21.4% |
| Q4 25 | $0.02 | $0.97 | ||
| Q3 25 | $-0.03 | $0.08 | ||
| Q2 25 | $-0.12 | $0.02 | ||
| Q1 25 | $0.31 | $0.53 | ||
| Q4 24 | $0.05 | $0.01 | ||
| Q3 24 | $0.09 | $0.20 | ||
| Q2 24 | $-0.01 | $0.17 | ||
| Q1 24 | $-0.19 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $4.2M | $846.7M |
| Total Assets | $30.2M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $89.0M | ||
| Q3 25 | $10.3M | $82.7M | ||
| Q2 25 | $9.8M | $73.5M | ||
| Q1 25 | $3.2M | $88.6M | ||
| Q4 24 | $2.8M | $99.7M | ||
| Q3 24 | $2.9M | $131.6M | ||
| Q2 24 | $2.6M | $127.5M | ||
| Q1 24 | $4.5M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $180.3M | ||
| Q2 24 | — | $177.4M | ||
| Q1 24 | — | $178.3M |
| Q4 25 | $4.2M | $846.7M | ||
| Q3 25 | $3.5M | $838.4M | ||
| Q2 25 | $3.8M | $837.7M | ||
| Q1 25 | $5.5M | $837.3M | ||
| Q4 24 | $681.0K | $832.3M | ||
| Q3 24 | $-332.0K | $832.2M | ||
| Q2 24 | $-1.9M | $830.4M | ||
| Q1 24 | $-2.1M | $828.9M |
| Q4 25 | $30.2M | $1.1B | ||
| Q3 25 | $30.5M | $1.1B | ||
| Q2 25 | $32.3M | $1.1B | ||
| Q1 25 | $30.6M | $1.1B | ||
| Q4 24 | $25.2M | $1.1B | ||
| Q3 24 | $24.9M | $1.1B | ||
| Q2 24 | $26.1M | $1.0B | ||
| Q1 24 | $26.8M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-2.9M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-2.9M | ||
| Q3 25 | $600.0K | $8.2M | ||
| Q2 25 | $6.9M | $-2.9M | ||
| Q1 25 | $490.0K | $-7.4M | ||
| Q4 24 | $-283.0K | $1.3M | ||
| Q3 24 | $311.0K | $13.7M | ||
| Q2 24 | $-1.8M | $-511.0K | ||
| Q1 24 | $-919.0K | $3.9M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | 0.11× | -1.61× | ||
| Q4 24 | -0.39× | 12.13× | ||
| Q3 24 | 0.24× | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
TCI
Segment breakdown not available.
